Alamar Biosciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Alamar Biosciences reported third-quarter 2026 revenue of $33.5 million, up 68% year over year from 19.9 million in the third quarter of 2025.
- Consumables revenue was 17.8 million, up 79% year over year and representing 53% of total revenue; instrument revenue was 8.5 million, up 50%, and service and other revenue was 7.2 million.
- Gross profit was 20.6 million and gross margin reached 61.5%, compared with 59.7% in the third quarter of 2025; management cited lower instrument costs, higher average selling prices for consumables, improved margins on tap services, and product mix.
- Total operating expenses were $35.8 million, compared with 19.8 million a year earlier; loss from operations was 15.1 million and net loss was 13.3 million.
- As of September 30th, 2026, Alamar had 231.5 million in cash, cash equivalents, short-term investments, and restricted cash.
- Biopharmaceutical companies accounted for 49% of third-quarter revenue, academic and research institutions 44%, and distributors 7%; the Americas represented 70% of revenue, EMEA 20%, and APAC 10%.
- Alamar was selected with Nightingale Health for the UK Biobank Vanguard study, which will profile 220 neurologically relevant proteins across 80,000 blood samples, and announced a GSK collaboration involving more than 60,000 serum samples.
- Alamar added more than 35 publications and preprints in Q3, bringing its cumulative total to more than 200; an Emory University study reported a 10 protein signature that distinguished ALS from healthy controls with 98% balanced accuracy in the validation cohort, compared with about 90% for NFL alone.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to Alamar Biosciences' third quarter 2026 financial results webcast call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Carrie Mendivil, VP of Investor Relations and Corporate Communications.
Good afternoon, everyone, and thank you for joining us today to review Alamar Biosciences' third quarter 2026 financial results. Joining me on the call are Yuling Luo, our Chief Executive Officer, and Justin McAnear, Chief Financial Officer. Our President, Tod White, will join for Q&A. Earlier this afternoon, we issued a press release detailing our third quarter financial results, and we posted an accompanying presentation to the investors section of our website. Before we begin, I'd like to remind you that statements we make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter.
To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the periodic reports that Alamar Biosciences files with the Securities and Exchange Commission. I'll now turn the call over to Yuling Luo, Alamar CEO.
Thank you, Carrie, and thank you all for joining us this afternoon. I will start our call with a brief overview of Alamar and our platform, then work through our Q3 business highlights and our strategy to unlock the opportunity ahead. I will then turn it over to Justin to cover our financials and update the full-year outlook. Starting on slide three, we founded Alamar with a bold mission, to enable the earliest detection of disease through precision proteomics. That purpose still guides every decision we make. Proteomics is one of the largest opportunities in life science, and it remains largely untapped. Researchers have long wanted to measure the proteins that signal disease, but the tools to sufficiently detect them have not existed. Alamar was built to solve that problem. Turning to slide four. Precision proteomics depends on five capabilities working together: ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation.
Other technologies have forced researchers to choose, giving up sensitivity to gain multiplexing or giving up depth to keep the workflow simple. Alamar is the only platform that delivers all five without compromise. Since we launched our precision proteomics platform in January 2024, customers have adopted rapidly, and that momentum continued this quarter. Turning to our top-line results on slide five. Total revenue for the third quarter grew 68% year-over-year, led by consumables, which grew 79% and made up 53% of total revenue. We also continue to improve our gross margin, which reached 61.5% for the first time in Q3. Based on this performance, we are raising our full-year revenue guidance. Turning to slide six. Our near-term growth strategy is powered by three drivers.
The first is expanding our installed base into new institutions and geographies. The second is building new content, both to deepen our position in neurology and inflammation, where we first established the platform, and move into adjacent disease areas with significant unmet need. The third is working with leading institutions and biopharma partners on new applications and large studies, which in turn grew our publication base and drives awareness and adoption. Turning to slide seven. We continue to make important progress across our business. It is increasingly clear that NULISA is the platform of choice to reach the low-abundance proteome, and that differentiation drove two significant recent wins. We were selected to deliver UK Biobank's Vanguard study of blood-based biomarkers for neurodegeneration, profiling 80,000 samples, and we were selected for a large-scale partnership with GSK, profiling more than 60,000 samples to advance its drug discovery program.
Our literature footprint grew to more than 200 publications and preprints, including a study in The Lancet Neurology that is the first longitudinal evaluation of a broad plasma biobank panel in patients receiving anti-amyloid therapy in real-world practice. We also strengthened our board and leadership team. Bob Ragusa, the former CEO of GRAIL and former Chief Operations Officer of Illumina, joined our board of directors. Bob helped scale two of the defining companies in genomics and early cancer detection, and believes the future of disease detection lies in multi-marker testing using proteins. His experience will be invaluable as we build towards clinical applications. We also welcome John Brottem as General Counsel and Amelia Merrill as Chief People Officer, as we scale the organization for our next phase of growth. Turning to slide eight. We continue to be inspired by the data and the biologic insight being generated by our customers.
At our user group meeting in October, customers shared exciting new data on treatment response in prostate cancer, healthy aging, and on protein quantitative trait loci, or pQTLs, which link genetic variation to protein levels. Much of this work is possible because of our ability to reach the low abundance proteome. Many of the proteins most relevant to disease, such as cytokines, signaling molecules, and the proteins released from the brain, circulating in blood at extremely low concentrations. Conventional approaches often cannot detect them reliably or at all, and the platform that measure many proteins at advance typically give up sensitivity as they scale. That gap matters most in the applications with greatest potential impact, including early detection of disease risk prediction, and minimal residual disease, where the signal of faint and the ultra-high sensitivity is essential.
NULISA was built for exactly this problem, measuring hundreds of low abundance proteins together from a small blood sample. That is why researchers and biopharma partners who need to reach this part of proteome at scale are turning to NULISA. This matters even more as the field turns to machine learning and the AI models built on proteomic data. These models learn what disease looks like by comparing it to health, so they need to see low abundance proteins measured accurately in healthy samples, where levels are often at their lowest. When a platform cannot detect a protein, that missing value is typically filled in statistically, and a model trained on that data risk learning patterns that reflect the gaps in the measurement rather than real biology.
Reliable detection across healthy and diseased sample gives these models a more accurate foundation, and we believe that will make data generated on our platform increasingly valuable as AI becomes central to biomarker discovery. Turning to slide nine. The UK Biobank study is an excellent example of the field recognizing the value of our platform. in October, together with Nightingale Health, we were selected to deliver UK Biobank's Vanguard study on blood-based biomarkers for neurodegenerative disease. Running on NULISA in Nightingale's laboratories, the study will profile 220 neurologically relevant proteins across 80,000 blood samples from individuals who were healthy when they enrolled. Funded by the Michael J. Fox Foundation, LifeArc, and ARUK, this study will create one of the world's largest open access resources for understanding the earliest molecular signs of neurodegeneration.
This will be the first time brain-derived and other low abundance proteins are measured from the UK Biobank, one of the most widely used health research resources in the world. It will also create the first definitive proteomics dataset for Parkinson's disease, the fastest growing neurological disorder, which affects more than 12 million people today. Together with Alzheimer's disease, which affects more than 55 million people worldwide, these diseases are usually diagnosed only after years or decades of molecular damage. Profiling people long before symptoms appear give us the chance to find the earliest signals when intervention is still possible. The study is expected to be complete by the end of 2027, and the data will be integrated with UK Biobank's imaging, genetic, and longitudinal health data, and made available to approved researchers worldwide. Turning to slide 10. Today, we announced a strategic scientific partnership with GSK, another strong validation of our platform by biopharma.
Together, we will study how circulating protein signatures related to disease progression, biological subtypes, and treatment response across respiratory, liver, kidney, neurological, and autoimmune conditions using real-world healthcare data that is far more representative of patients than clinical trials. The work will focus on linking protein signals to clinical outcomes, identify new biomarkers, uncovering the biological subtype beneath a single diagnosis, and understanding how patients respond to existing therapies. Patients who share the diagnosis often have biologically distinct disease, and that remain one of the central challenges in drug development. We believe NULISA can help stratify patients at the earliest possible stage and improve how disease is classified and treated. To support the collaboration, we will profile more than 60,000 serum samples using NULISAseq Immune 340 panel and the Neuro 220 panel.
This partnership will create one of the most comprehensive biomarker datasets applied to GSK's drug discovery program and allow Alamar to potentially develop and commercialize novel protein signatures in precision prevention, treatment, and earlier disease detection. Turning to slide 11. Our scientific footprint continues to grow. We added more than 35 publications and pre-prints in Q3, bringing our cumulative total to more than 200 across neurodegenerative disease, oncology, and autoimmune conditions. Several of these studies show our newest product already at work. Just three months after launch, the first pre-print using our eMTBR-Tau assay supports its use in staging Alzheimer's disease. A publication in Nature Medicine also supports new applications for our platform in women's health.
An independent study from Emory University published in Nature Communications identified a 10-protein signature that distinguished ALS from healthy controls with 98% balanced accuracy in a validation cohort, compared with about 90% for NfL alone. It's a clear example of why measuring many proteins at once matters. Each new study adds independent evidence of what NULISA can do and helps bring new researchers to our platform. Turning to slide 12. One of the most exciting things for us is seeing NULISA generate new insight in translational setting. A study from Dr. Carlos Cruchaga's lab at the Washington University published this quarter in The Lancet Neurology is a great example. It is the first longitudinal study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid therapy in routine clinical practice.
Using our NULISAseq CNS 120 panel, researchers measured 130 proteins across nearly 2,400 samples from patients treated with lecanemab and from untreated comparison group using just 25 microliters of plasma per sample. The findings address one of the biggest open questions in Alzheimer's care: why clearing amyloid does not deliver the same clinical benefit for every patient. The proteins associated with amyloid clearance were largely different from those associated with later cognitive decline, which suggests two reflect distinct biologic processes. Among treated patients, 34 of the 130 biomarkers changed significantly over the course of therapy, and they did not all move in the same direction. The study also shows why sensitivity and specificity matter. Brain-derived tau consistently outperformed the same protein circulating in the rest of the body, accounting for four of the top five markers that distinguish the treated patient from the controls.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
